AA
NBIX icon

AlphaCentric Advisors’s Neurocrine Biosciences NBIX Stock Holding History

AlphaCentric Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Buy
9,727
+120
+1% +$17.8K 1.39% 7
2026
Q1 		$1.27M Buy
9,607
+2,224
+30% +$295K 1.26% 13
2025
Q4 		$1.05M Buy
+7,383
New +$1.07M 1.04% 17
2024
Q4 		$503K Sell
3,684
-18,816
-84% -$2.33M 0.5% 56
2024
Q3 		$2.59M Buy
22,500
+15,500
+221% +$2.12M 1.93% 6
2024
Q2 		$964K Hold
7,000
– – 0.71% 49
2024
Q1 		$965K Buy
+7,000
New +$956K 0.58% 64
2023
Q4 		– Sell
-30,000
Closed -$3.38M – 269
2023
Q3 		$3.38M Sell
30,000
-6,500
-18% -$684K 1.91% 9
2023
Q2 		$3.44M Buy
36,500
+21,000
+135% +$2.05M 1.91% 7
2023
Q1 		$1.57M Buy
+15,500
New +$1.61M 1.08% 22
2021
Q2 		– Sell
-2,000
Closed -$195K – 233
2021
Q1 		$195K Sell
2,000
-800
-29% -$83.9K 0.07% 94
2020
Q4 		$268K Buy
2,800
+2,500
+833% +$241K 0.11% 47
2020
Q3 		$29K Buy
300
+75
+33% +$8.68K 0.01% 131
2020
Q2 		$27K Buy
+225
New +$24.9K 0.02% 107

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

AlphaCentric Advisors's NBIX Position: Q2 2026 in Review

AlphaCentric Advisors increased its Neurocrine Biosciences (NBIX) stake by 1.2% in Q2 2026, buying an estimated $17.8K and bringing the position to 9,727 shares worth $1.64M. The position accounts for 1.39% of the portfolio, ranked #7.

AlphaCentric Advisors first reported a position in NBIX in Q2 2020 and has held it in 14 quarters since. The position peaked at $3.44M in Q2 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • AlphaCentric Advisors held 9,727 shares of Neurocrine Biosciences worth $1.64M as of Q2 2026.
  • AlphaCentric Advisors bought 120 Neurocrine Biosciences shares in Q2 2026, an estimated $17.8K.
  • Neurocrine Biosciences made up 1.39% of AlphaCentric Advisors's portfolio in Q2 2026, its #7 holding.
  • AlphaCentric Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and has held it in 14 quarters since.
  • AlphaCentric Advisors's Neurocrine Biosciences position peaked at $3.44M in Q2 2023.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.